These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32936919)

  • 1. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
    Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV.
    Hwang YJ; Lesko CR; Brown TT; Alexander GC; Zalla LC; Keruly JC; Snow LN; Pytell JD; Falade-Nwulia O; Jones JL; Moore RD; Fojo AT
    AIDS; 2024 Sep; 38(11):1696-1702. PubMed ID: 38864578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
    Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
    J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
    Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
    PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
    Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
    Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
    Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
    J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
    Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
    HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines.
    El Bouzidi K; Jose S; Phillips AN; Pozniak A; Ustianowski A; Gompels M; Winston A; Schaap A; Dunn DT; Sabin CA;
    AIDS; 2020 Oct; 34(12):1823-1831. PubMed ID: 32516283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada.
    Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD
    Clin Infect Dis; 2021 Oct; 73(7):e1408-e1414. PubMed ID: 32780095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
    Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
    HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.